Lexicon Pharmaceuticals | LXRX - DEBITO





DEBITO Cambiamento Data
Abbott USD 13.86B 919M 2025-12
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Agios Pharmaceuticals USD 44.52M 4.24M 2025-09
Akebia Therapeutics USD 46.51M 7.82M 2025-03
Alnylam Pharmaceuticals USD 1.31B 11.39M 2025-09
AstraZeneca USD 32.63B 207M 2025-09
BioMarin Pharmaceutical USD 604.24M 375K 2025-09
Coherus Biosciences USD 294.92M 1.25M 2025-03
Eli Lilly USD 42.51B 2.6B 2025-09
Esperion Therapeutics USD 262.92M 1.76M 2024-09
Halozyme Therapeutics USD 1.51B 1.66M 2025-09
Illumina USD 2.58B 22M 2025-09
Insmed USD 727.89M 163.33M 2025-12
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
J&J USD 47.93B 2.14B 2025-12
Lexicon Pharmaceuticals USD 99.51M 243K 2023-12
MacroGenics USD 37.01M 238K 2025-09
MannKind USD 119.91M 73.09M 2025-09
Merck USD 41.37B 5.97B 2025-09
Moderna USD 734M 7M 2025-09
Novartis USD 32.64B 1.37B 2025-06
PTC Therapeutics USD 286.32M 306K 2025-09
Puma Biotechnology USD 89.06M 55.07M 2024-06
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
Thermo Fisher Scientific USD 35.68B 451M 2025-09
Ultragenyx Pharmaceutical USD 33.83M 2.46M 2025-09
United Therapeutics USD 200M 100M 2025-03
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12